Breaking News
Get 40% Off 0
June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date. Unlock Stocks
Close

Poxel SA (POXEL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.64 +0.01    +1.75%
03/06 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR0012432516 
  • Volume: 217,674
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.63 - 0.66
Poxel SA 0.64 +0.01 +1.75%

Poxel SA Company Profile

 
Get an in-depth profile of Poxel SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company’s lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Contact Information

Address Immeuble Le Sunway 259-261 Avenue Jean JaurEs
Lyon, 69007
France
Phone 33 1 44 71 94 94
Fax -

Top Executives

Name Age Since Title
Richard N. Kender 68 2015 Independent Director
Pascale Boissel 58 2015 Independent Director
Harold E. Lebovitz - - Member of Scientific Advisory Board
Hirotaka Watada - - Member of Scientific Advisory Board
Kohjiro Ueki - - Member of Scientific Advisory Board
Keith van Haren - 2021 Member of Scientific Advisory Board
Kohei Kaku - 2019 Member of Scientific Advisory Board
Thomas Kuhn - 2009 Co-Founder, CEO & Director
Mohammed Khoso Baluch - 2012 Independent Chairman of the Board
S. Ali Fatemi - 2021 Member of Scientific Advisory Board ?
Stephan Kemp - 2021 Member of Scientific Advisory Board
Vlad Raziu - 2020 Member of the Scientific Advisory Board
Gregory Steinberg - 2020 Member of Scientific Advisory Board
Masato Kasuga - 2019 Member of Scientific Advisory Board
Stephen A. Harrison - 2019 Member of Scientific Advisory Board
Wataru Ogawa - - Member of Scientific Advisory Board
Florian Eichler - 2021 Member of Scientific Advisory Board
Quentin Anstee - 2020 Member of the Scientific Advisory Board
Arun J. Sanyal - 2020 Member of the Scientific Advisory Board
Kenneth Cusi - 2019 Member of Scientific Advisory Board
John F. Amatruda - - Member of Scientific Advisory Board
Marc Engelen - 2021 Member of Scientific Advisory Board
Ralph A. Defronzo - 2019 Member of Scientific Advisory Board
Fanny Mochel - 2021 Member of Scientific Advisory Board
Jaspreet Singh - 2021 Member of Scientific Advisory Board
Philip Newsome - 2021 Member of the Scientific Advisory Board
Edouard Guillet - 2022 Observer to the Board of Directors
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

POXEL Comments

Write your thoughts about Poxel SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email